Nektar Therapeutics, a California-based biopharmaceutical company, has made significant strides in the field of immunotherapy both domestically and internationally. Its innovative portfolio includes rezpegaldesleukin, a cytokine Treg stimulant that has advanced to phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis. The drug is also in phase 1B clinical trial to treat atopic dermatitis and psoriasis. Furthermore, the company's NKTR-255, an IL-15 receptor agonist, is currently in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, as well as head and neck cancer squamous cell carcinoma and colorectal cancer. Nektar Therapeutics has established collaboration agreements with prominent industry leaders such as Takeda Pharmaceutical Company Ltd; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Since its inception in 1990, Nektar Therapeutics has continually pushed the envelope in the realm of immunotherapy, and remains at the forefront of this rapidly evolving field.
Nektar Therapeutics's ticker is NKTR
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 501-1000 employees working at Nektar Therapeutics
It is http://www.nektar.com
Nektar Therapeutics is in the Healthcare sector
Nektar Therapeutics is in the Drug Delivery industry
The following five companies are Nektar Therapeutics's industry peers: